A fifth-generation TAVR valve from Edwards Lifesciences was associated with improved outcomes compared to the device's predecessors in a new real-world analysis out of Cedars Sinai.
The study, presented at the Society of Interventional Radiology Annual Scientific Meeting, marks one of the first to use freezing on large tumors in the breast.
While the American College of Cardiology's annual meeting has historically had a more clinical focus, presentations at this year's conference in Atlanta will spend much more time looking at the business side of things.